Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20215746 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9945539 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1582511 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9964305 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL705500 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL859968 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25400489 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16572007 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12170354 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17972429 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230183283-A1 | NOVEL GLYCOSIDE COMPOUND AND PRODUCTION METHOD THEREFOR | BONAC CORPORATION (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20230183746-A1 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2023-03-02 | — | — | US | disclosed |
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | EMORY UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9988415-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2018-06-05 | — | — | US | disclosed |
| WO-2017155923-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| US-8536318-B2 | Chemical RNA synthesis method | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-09-17 | — | — | US | disclosed |
| US-8470987-B2 | Protective group for synthesis of RNA and derivative | CHIRALGEN, LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8470987-B2 | Protective group for synthesis of RNA and derivative | CHIRALGEN, LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120238737-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8202983-B2 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110275793-A1 | Chemical RNA Synthesis Method | CHEMGENES CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-20110178284-A1 | Novel protective group for synthesis of RNA and derivative | CHIRALGEN, LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20090209479-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | SNRPE, DDX21, DCLRE1B | SLC28A1 479/4885SLC28A2 505/4885SLC29A1 704/4885 |
| US-20230183283-A1 | NOVEL GLYCOSIDE COMPOUND AND PRODUCTION METHOD THEREFOR | SLC5A11, POLRMT, MAPK11 | SLC28A1 101/4885SLC28A2 172/4885SLC29A1 268/4885 |
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | PNP, NTPCR, TYMP | SLC28A1 47/4885SLC28A2 50/4885SLC29A1 32/4885 |
| US-20110275793-A1 | Chemical RNA Synthesis Method | NSUN3, POLR2E, POLR2H | SLC28A1 3400/4885SLC28A2 3292/4885SLC29A1 2445/4885 |
| US-20110178284-A1 | Novel protective group for synthesis of RNA and derivative | RNGTT, FBL, RNASEH1 | SLC28A1 1519/4885SLC28A2 1434/4885SLC29A1 1422/4885 |
| US-20120238737-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | NSUN3, NSUN2, TRDMT1 | SLC28A1 503/4885SLC28A2 400/4885SLC29A1 183/4885 |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, SNRPB2, RNGTT | SLC28A1 1638/4885SLC28A2 1429/4885SLC29A1 1209/4885 |
| US-20090209479-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | NSUN3, NSUN2, TRDMT1 | SLC28A1 503/4885SLC28A2 400/4885SLC29A1 183/4885 |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, RNGTT, RNMT | SLC28A1 1486/4885SLC28A2 1426/4885SLC29A1 1026/4885 |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, PNP, NTPCR | SLC28A1 46/4885SLC28A2 51/4885SLC29A1 31/4885 |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, NTPCR, PNP | SLC28A1 40/4885SLC28A2 48/4885SLC29A1 29/4885 |
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | GSS, GSR, RNMT | SLC28A1 177/4885SLC28A2 202/4885SLC29A1 36/4885 |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | SLC28A1 434/4885SLC28A2 533/4885SLC29A1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.